KPT-330-mediated XPO1 inhibition impairs homologous recombination and enhances radiosensitivity in extranodal NK/T-cell lymphoma.
A drug called selinexor can sensitize a rare, radiation-resistant lymphoma to radiotherapy by blocking a specific DNA repair pathway, warranting clinical trials.
This study identifies the XPO1-c-Myc-RAD51/CHEK1 axis as a druggable HR repair vulnerability in ENKTL and shows that KPT-330 (selinexor) synergizes with radiotherapy in xenografts and 2 R/R clinical cases. The mechanistic rationale for KPT-330-based radiosensitization supports prospective trial development for this rare, radioresistant lymphoma with high unmet need.
What the study was
- Study design
- Mechanistic study (in vitro + xenograft) with 2 R/R clinical cases
- Population
- ENKTL cell lines, xenograft models, and 2 heavily pretreated R/R ENKTL patients
- Sample size
- 2
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- British Journal of Cancer
Why it surfaced
ENKTL is a rare aggressive lymphoma with high unmet need; the mechanistic rationale is solid (HR repair vulnerability) and selinexor is an approved agent. Clinical evidence is very limited (n=2), capping score at 6.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.